These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8941198)

  • 61. Severe Acute Toxicity of Inhaled Nicotine and e-Cigarettes: Seizures and Cardiac Arrhythmia.
    Shao XM; Fang ZT
    Chest; 2020 Mar; 157(3):506-508. PubMed ID: 32145810
    [No Abstract]   [Full Text] [Related]  

  • 62. Which smokers are helped to give up smoking using transdermal nicotine patches? Results from a randomized, double-blind, placebo-controlled trial.
    Yudkin PL; Jones L; Lancaster T; Fowler GH
    Br J Gen Pract; 1996 Mar; 46(404):145-8. PubMed ID: 8731618
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Saliva nicotine as an index of plasma levels in nicotine skin patch users.
    Rose JE; Levin ED; Benowitz N
    Ther Drug Monit; 1993 Oct; 15(5):431-5. PubMed ID: 8249050
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Steady-state pharmacokinetics and dose relationship of nicotine delivered from Nicoderm (Nicotine Transdermal System).
    Gorsline J; Gupta SK; Dye D; Rolf CN
    J Clin Pharmacol; 1993 Feb; 33(2):161-8. PubMed ID: 8440766
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dose-related cardiovascular and endocrine effects of transdermal nicotine.
    Zevin S; Jacob P; Benowitz NL
    Clin Pharmacol Ther; 1998 Jul; 64(1):87-95. PubMed ID: 9695723
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation.
    Lerman C; Tyndale R; Patterson F; Wileyto EP; Shields PG; Pinto A; Benowitz N
    Clin Pharmacol Ther; 2006 Jun; 79(6):600-8. PubMed ID: 16765148
    [TBL] [Abstract][Full Text] [Related]  

  • 67. High-dose nicotine patch therapy for smokers with a history of alcohol dependence: 36-week outcomes.
    Kalman D; Kahler CW; Garvey AJ; Monti PM
    J Subst Abuse Treat; 2006 Apr; 30(3):213-7. PubMed ID: 16616165
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Nicotine alters some of cocaine's subjective effects in the absence of physiological or pharmacokinetic changes.
    Kouri EM; Stull M; Lukas SE
    Pharmacol Biochem Behav; 2001; 69(1-2):209-17. PubMed ID: 11420088
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bioavailability and absorption kinetics of nicotine following application of a transdermal system.
    Gupta SK; Benowitz NL; Jacob P; Rolf CN; Gorsline J
    Br J Clin Pharmacol; 1993 Sep; 36(3):221-7. PubMed ID: 9114908
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The effects of transdermal nicotine on inspection time.
    Thompson JC; Wilby G; Stough C
    Hum Psychopharmacol; 2002 Apr; 17(3):157-61. PubMed ID: 12404693
    [TBL] [Abstract][Full Text] [Related]  

  • 71. CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy.
    Lee AM; Jepson C; Shields PG; Benowitz N; Lerman C; Tyndale RF
    Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1312-4. PubMed ID: 17548706
    [No Abstract]   [Full Text] [Related]  

  • 72. A transdermal nicotine patch is not effective for postoperative pain management in smokers: a pilot dose-ranging study.
    Olson LC; Hong D; Conell-Price JS; Cheng S; Flood P
    Anesth Analg; 2009 Dec; 109(6):1987-91. PubMed ID: 19923530
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A new gas chromatography-mass spectrometry method for simultaneous determination of total and free trans-3'-hydroxycotinine and cotinine in the urine of subjects receiving transdermal nicotine.
    Ji AJ; Lawson GM; Anderson R; Dale LC; Croghan IT; Hurt RD
    Clin Chem; 1999 Jan; 45(1):85-91. PubMed ID: 9895342
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacokinetic disposition of multiple-dose transdermal nicotine in healthy adult smokers.
    Kochak GM; Sun JX; Choi RL; Piraino AJ
    Pharm Res; 1992 Nov; 9(11):1451-5. PubMed ID: 1475232
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of transdermal nicotine delivery on cognitive outcomes: A meta-analysis.
    Majdi A; Sadigh-Eteghad S; Gjedde A
    Acta Neurol Scand; 2021 Aug; 144(2):179-191. PubMed ID: 33899218
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling.
    Sachs DP; Säwe U; Leischow SJ
    Arch Intern Med; 1993 Aug; 153(16):1881-90. PubMed ID: 8110249
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Transdermal nicotine substitution: pharmacokinetics of nicotine and cotinine.
    Keller-Stanislawski B; Caspary S; Merz PG; Bonn R; Wolff M; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1993 Sep; 31(9):417-21. PubMed ID: 8225689
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cotinine: effects with and without nicotine.
    Hatsukami D; Pentel PR; Jensen J; Nelson D; Allen SS; Goldman A; Rafael D
    Psychopharmacology (Berl); 1998 Jan; 135(2):141-50. PubMed ID: 9497019
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Transdermal nicotine for induction of remission in ulcerative colitis.
    McGrath J; McDonald JW; Macdonald JK
    Cochrane Database Syst Rev; 2004 Oct; (4):CD004722. PubMed ID: 15495126
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The effect of transdermal nicotine patches on sleep and dreams.
    Page F; Coleman G; Conduit R
    Physiol Behav; 2006 Jul; 88(4-5):425-32. PubMed ID: 16782142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.